Semaglutide Revenue and What It Reveals About Weight-Loss Medicine

What the revenue figures actually reflect

Pharmaceutical sales data for semaglutide are striking enough that they occasionally get quoted out of context. Novo Nordisk's annual results show semaglutide-based products contributed revenues that propelled the company into the top tier of European market capitalisation by 2024. The detail that matters clinically is why that happened.

The income followed the evidence. The STEP programme (a series of large, randomised controlled trials) established semaglutide 2.4mg as a weight-management medicine with a clinically meaningful effect. STEP 1, published in the New England Journal of Medicine, reported around 15% average weight reduction over 68 weeks in adults with obesity or overweight and at least one weight-related condition. NICE's subsequent recommendation for Wegovy under technology appraisal TA875 in 2023 gave the UK clinical community a formal endorsement based on that data. When evidence is strong and patient need is large, commercial scale tends to follow. That sequence matters: the revenue is a downstream consequence of a robust trial programme, not a substitute for one.

A common misconception is that high-revenue medicines must be overhyped relative to their actual effect. For semaglutide, the clinical record doesn't support that reading, the figures in the trials are consistent across different populations and trial arms, which is part of why prescribers and regulators took them seriously.

For anyone curious about the broader treatment landscape, the semaglutide overview on our site covers how the medicine works and what to expect from treatment.

Wegovy revenue in 2024 and what drove it

Wegovy's specific contribution to semaglutide revenue grew sharply through 2023 and 2024 as supply constraints eased and access in the UK and US expanded. Globally, demand for Wegovy as a weight-management product outpaced almost every forecast Novo Nordisk had published. In the UK context, NICE's TA875 recommendation (and NHS England's phased commissioning through specialist weight management services) created an institutional route to access alongside the private market.

The 2024 revenue picture for Wegovy also reflected the cardiovascular indication. Semaglutide received authorisation to reduce the risk of major cardiovascular events in eligible adults, broadening prescribing beyond pure weight management. Then in July 2026 came a further UK approval: semaglutide (Wegovy) was conditionally authorised by the MHRA to treat MASH, a form of fatty liver disease in adults with moderate-to-advanced fibrosis. Each new indication adds both patients and revenue, but it also adds to the post-marketing safety dataset, which benefits everyone taking the medicine.

If you want a fuller picture of how Wegovy's 2024 revenue broke down, that page examines the figures in more detail, including the supply dynamics that shaped UK availability.

What scale means for supply chain and safety in the UK

The volume of semaglutide manufactured and distributed globally has two practical consequences for UK patients. First, the medicine now moves through an established, well-documented supply chain. Eli Lilly's tirzepatide and Novo Nordisk's semaglutide both come to UK patients through licensed wholesalers; a GPhC-registered pharmacy like ours sources through that authorised route. Second, large commercial volumes attract counterfeit interest. The MHRA has warned repeatedly about fake weight-loss pens sold through social media and unregistered websites. Some seized fakes contained insulin rather than semaglutide, which caused serious harm to people who injected them. Verifying that your pharmacy appears on the GPhC register before ordering is the simplest protection against that risk.

For patients, the practical question isn't how much Novo Nordisk earned last year. It's whether the medicine is genuine, clinically appropriate, and properly supervised. Those questions are answered by the prescriber's assessment and the pharmacy's registration status, not by sales charts. Our clinical team explains how we approach each consultation.

Where the clinical development goes from here

Semaglutide's revenue trajectory is still rising, partly because the medicine's clinical scope keeps expanding. Patients moving up through the dosing schedule, including those reaching the semaglutide 1mg stage of their titration, represent a meaningful portion of people currently in treatment across the UK. That development is funded, in part, by the commercial returns on earlier products, which is how pharmaceutical research economics work. Patients benefit when that cycle produces better-tolerated formulations and higher-efficacy dose options.

It is also worth noting that semaglutide now exists in oral form for weight management. The MHRA approved Wegovy tablets in June 2026, the first oral GLP-1 medicine licensed in the UK for this purpose. The route to accessing Wegovy (whether injection or tablet) begins with a clinical consultation, not a purchase. Anyone considering treatment can read about the full range of licensed weight-loss treatments before deciding whether to proceed.

Semaglutide's commercial story is, at its core, a story about a medicine that works well enough for millions of people to seek it out. The numbers confirm scale. They don't replace the conversation you need to have with a prescriber about whether it's right for you, and that conversation should also cover side effects such as the dizziness and fainting that some people experience on Wegovy. If you'd like that conversation, starting a free consultation with our team is straightforward.